INTRODUCTION: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the medical community has faced major challenges that affect disease management in all areas . Dermatologists and immunologists have to choose appropriate treatment strategy taking into consideration risk of infection and possible exacerbation of the course of the disease in patients with confirmed infection . Management of atopic dermatitis (AD) in moderate to severe cases is based on systemic therapy such as cyclosporine, azathioprine, methotrexate and dupilumab . Areas covered: A literature search in PubMed database was performed until 6 March 2021 . In this review, the authors discuss non-biologic and biologic systemic medications for AD and provide an overview of therapeutic recommendations during COVID-19 pandemic . EXPERT OPINION: In case of an active COVID-19 infection, conventional systemic treatment and biological treatment needs to be stopped until clinical recovery . Noninfected patients with systemic treatment of AD should continue their therapy via self-application . The authors can conclude that understanding of dupilumab therapy is better recognized in context AD treatment during COVID-19 pandemic in comparison to cyclosporine, azathioprine and methotrexate . However, this systemic immunosuppressants still require further investigation and literature complementation.